PT  - JOURNAL ARTICLE
AU  - Mahdi, Haider
AU  - Ray-Coquard, Isabelle
AU  - Lorusso, Domenica
AU  - Mirza, Mansoor Raza
AU  - Monk, Bradley J
AU  - Slomovitz, Brian
TI  - Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
AID  - 10.1136/ijgc-2023-004454
DP  - 2023 Nov 01
TA  - International Journal of Gynecologic Cancer
PG  - 1675--1681
VI  - 33
IP  - 11
4099  - http://ijgc.bmj.com/content/33/11/1675.short
4100  - http://ijgc.bmj.com/content/33/11/1675.full
SO  - Int J Gynecol Cancer2023 Nov 01; 33
AB  - Endometrial cancer is the most common gynecologic malignancy in developed countries, with increasing incidence and mortality rates worldwide. While most cases are successfully treated with surgery, first-line treatment options for metastatic or recurrent endometrial cancer involve significant toxicities. Imprecise classification of heterogeneous subgroups further complicates treatment decisions and interpretation of clinical trial results. Recent advances in molecular classification are guiding treatment decisions for metastatic or recurrent endometrial cancers. Integrating molecular characteristics with traditional clinicopathology can both reduce overtreatment or undertreatment and help guide the appropriate choice of therapies and effective design of future studies. Here we discuss the treatment of metastatic or recurrent low-grade endometrioid adenocarcinoma of the uterine corpus, which is distinct from high-grade tumors histologically, molecularly, and in treatment response.